阿尔茨海默病研发不易，诺和诺德、强生新药试验接连失败！

制药网12-02

阿尔茨海默病(AD)俗称“老年痴呆症”，是一种严重的神经退行性疾病，该病存在巨大未满足的需求，然而，其药物研发却一直伴随着失败。近期，阿尔茨海默病疗法的开发就接连遭遇滑铁卢。11月24日，诺和诺德公布司美格鲁肽(Ozempic和Wegovy的有效成分)口服片剂，在治疗阿尔茨海默病两项大型III期临床试验中未能达到主要临床终点，试验失败。该项临床试验涉招募了约3800名已接受标准治疗的阿尔茨海默...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2588408504?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-02 11:20","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2588408504","market":"us","top_or_hot":-1,"title":"阿尔茨海默病研发不易，诺和诺德、强生新药试验接连失败！","media":"制药网","content":"<div>\n<p>阿尔茨海默病(AD)俗称“老年痴呆症”，是一种严重的神经退行性疾病，该病存在巨大未满足的需求，然而，其药物研发却一直伴随着失败。近期，阿尔茨海默病疗法的开发就接连遭遇滑铁卢。11月24日，诺和诺德公布司美格鲁肽(Ozempic和Wegovy的有效成分)口服片剂，在治疗阿尔茨海默病两项大型III期临床试验中未能达到主要临床终点，试验失败。该项临床试验涉招募了约3800名已接受标准治疗的阿尔茨海默...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202112442978aec9d&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>阿尔茨海默病研发不易，诺和诺德、强生新药试验接连失败！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n阿尔茨海默病研发不易，诺和诺德、强生新药试验接连失败！\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-02 11:20 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202112442978aec9d&s=b><strong>制药网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>阿尔茨海默病(AD)俗称“老年痴呆症”，是一种严重的神经退行性疾病，该病存在巨大未满足的需求，然而，其药物研发却一直伴随着失败。近期，阿尔茨海默病疗法的开发就接连遭遇滑铁卢。11月24日，诺和诺德公布司美格鲁肽(Ozempic和Wegovy的有效成分)口服片剂，在治疗阿尔茨海默病两项大型III期临床试验中未能达到主要临床终点，试验失败。该项临床试验涉招募了约3800名已接受标准治疗的阿尔茨海默...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202112442978aec9d&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0122379950.USD","symbol_name":"贝莱德世界健康科学A2","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202112442978aec9d&s=b","article_id":"2588408504","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202112442978aec9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2588408504","pubTimestamp":1764645651,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"近期，阿尔茨海默病疗法的开发就接连遭遇滑铁卢。在同一时期，强生的阿尔茨海默病项目之一也宣布失败。虽然近期多家药企在阿尔茨海默病药物研发方面遭遇滑铁卢，但在众多药企涌入该赛道持续推动创新的背景下，还是有不少药企迎来了好消息。如万邦德、绿叶制药等多家国内药企就相继公布了阿尔茨海默病研究新进展。LY03017拟用于治疗阿尔茨海默病精神病性障碍、帕金森病精神病性障碍、精神分裂症阴性症状。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0122379950.USD":"贝莱德世界健康科学A2","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU2430703095.HKD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (HKD) INC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU1221951129.SGD":"NORDEA 1 STABLE RETURN \"HM\" (SGDHDG) INC","BK4592":"伊斯兰概念","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","BK4504":"桥水持仓","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","JNJ":"强生","BK4568":"美国抗疫概念","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","BK4588":"碎股","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4007":"制药","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","NVO":"诺和诺德","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","BK4581":"高盛持仓","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","BK4585":"ETF&股票定投概念","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","BK4534":"瑞士信贷持仓","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc"},"translate_title":"The research and development of Alzheimer's disease is not easy, Novo Nordisk and Johnson & Johnson's new drug trials have failed one after another!","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.5,"JNJ":1.5},"content_text":"阿尔茨海默病(AD)俗称“老年痴呆症”，是一种严重的神经退行性疾病，该病存在巨大未满足的需求，然而，其药物研发却一直伴随着失败。近期，阿尔茨海默病疗法的开发就接连遭遇滑铁卢。11月24日，诺和诺德公布司美格鲁肽(Ozempic和Wegovy的有效成分)口服片剂，在治疗阿尔茨海默病两项大型III期临床试验中未能达到主要临床终点，试验失败。该项临床试验涉招募了约3800名已接受标准治疗的阿尔茨海默病患者，初步结果显示，口服司美格鲁肽安全性良好，且改善一些与疾病相关的生物标志物，但最终数据显示，与安慰剂相比，该药物未能显著减缓患者记忆力或认知能力的下降(两项有效性终点)。在同一时期，强生的阿尔茨海默病项目之一也宣布失败。其抗tau抗体posdinemab在一项二期临床研究中未能减缓早期阿尔茨海默病患者的认知和功能下降速度，继续推进研究也无法实现预设目标。基于这一判断，强生停止了研究。资料显示，posdinemab主要针对早期AD患者。2025年1月8日，该药获批进入FDA快速通道，成为该公司AD产品线中第二款进入快速通道的疗法。尽管 posdinemab 折戟，但强生并未完全退出 AD 研发。其还在推进另一款 tau 靶向疗法 ——JNJ-2056。这是一款 tau 主动免疫疗法，主要针对临床前期AD人群，现已进入二期临床。虽然近期多家药企在阿尔茨海默病药物研发方面遭遇滑铁卢，但在众多药企涌入该赛道持续推动创新的背景下，还是有不少药企迎来了好消息。如万邦德、绿叶制药等多家国内药企就相继公布了阿尔茨海默病研究新进展。11月28日，万邦德透露公司石杉碱甲控释片(FN12)的II/III期关键注册临床进展顺利。据悉，石杉碱甲在适当剂量下可显著改善患者的认知功能。同时，临床前研究显示，石杉碱甲不仅能提升脑内胆碱水平，还具有抗炎、抗氧化、降低β淀粉样蛋白水平、线粒体保护、神经元保护等综合作用。11月24日，绿叶制药宣布，其自主研发的新一代5-羟色胺2A型受体(5-HT2AR)反向激动剂和5-羟色胺2C型受体(5-HT2CR)拮抗剂LY03017已获得美国FDA许可开展临床试验。LY03017拟用于治疗阿尔茨海默病精神病性障碍、帕金森病精神病性障碍、精神分裂症阴性症状。目前，该药也在中国处于1期临床阶段。11月17日，康方生物自主研发的协同靶向Aβ和BBB高表达受体的双特异性抗体新药AK152，获NMPA批准开展阿尔茨海默病临床试验。总的来说，尽管面临众多研发难题和较高的失败率，但AD治疗药物庞大且不断增长的市场规模，仍将不断吸引国内外创新药企业入局。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588408504","isCrawlerRequest":true}